Table 1 Characteristics of the 216 conventional (clear cell) renal cancer patients included in the study. Median follow-up time was 7 years 1 month
Characteristic | n (%) | Characteristic | Divisions | Median (range) |
|---|---|---|---|---|
Age (years) | ||||
Median | 64 | Hb (g dl−1) | 13.6 (7–20) | |
Range | 29–85 | |||
Gender | ||||
Male | 130 (60) | RBC ( × 1012 l−1) | 4.6 (2.8–14.7) | |
Female | 86 (40) | |||
Grade | ||||
1 | 4 (2) | WBC ( × 109 l−1) | 7.7 (3.2–607) | |
2 | 48 (22) | |||
3 | 105 (49) | |||
4 | 58 (27) | |||
Unknown | 1 (0) | |||
Max tumour size (cm) | ||||
Median | 6.5 | Platelets (x109 l−1) | 284 (87–884) | |
Range | 0.7–18 | |||
pT stage | ||||
1 | 82 (38) | Sodium (mmol l−1) | 140 (127–147) | |
2 | 20 (9) | |||
3 | 111 (51.5) | |||
4 | 2 (1) | |||
Unknown | 1 (0.5) | |||
N stage | ||||
0 | 171 (79) | Potassium (mmol l−1) | 4.4 (3.1–6.0) | |
1+ | 40 (19) | Unknown | 4 (2) | |
Unknown | 5 (2) | |||
M stage | ||||
0 | 164 (76) | Creatinine (μmol l−1) | 95 (52–1106) | |
1 | 52 (24) | |||
TNM stage | ||||
I | 75 (35) | CRP (mg l−1) | 7.6 (<5–266) | |
II | 14 (6) | ⩽15 | 152 (70%) | |
IIIa | 74 (34.5) | >15 | 64 (30%) | |
IV | 52 (24) | |||
Unknown | 1 (0.5) | |||
CT T stage | ||||
1a | 47 (22) | Osteopontin (ng ml−1) | 98 (6.6–1231) | |
1b | 62 (28.5) | ⩽135 | 140 (65%) | |
2 | 52 (24) | >135–230 | 39 (18%) | |
3 | 39 (18) | >230 | 37 (17%) | |
4 | 10 (5) | |||
Unknown | 6 (2.5) | |||
CT tumour size (cm) | ||||
Median | 5.9 | CA9 (pg ml−1) | 109 (12–1049) | |
Range | 2–21 | ⩽225 | 175 (81%) | |
Unknown | 16 (7) | >225 | 41 (19%) | |
Symptom score b | ||||
1 | 90 (42) | Urea (mmol l−1) | 5.7 (2–28.8) | |
2 | 72 (33) | |||
3 | 52 (24) | |||
Unknown | 2 (1) | |||
